Preclusion
Developing a heart implant to detect early signs of reduced blood flow for people at risk of heart muscle damage
Highlights
- Young companyFounded 2025
- New on EvolcAdded 2026-11-09
About Preclusion
Preclusion is developing H-Guard, a long-term implant intended to detect local biochemical signs of reduced blood flow to the heart. Its ceramic sensing element is designed to convert local potassium differences into an electrical signal.
The company aims to enable earlier treatment to prevent irreversible heart muscle damage. PRECLUSION LTD was founded in 2025 and is registered in London, United Kingdom.
Product: H-Guard, a long-term implant in development that aims to detect local biochemical signs of reduced blood flow to the heart.
Jobs at Preclusion
More media & content companies
Preloaded
Designs playful digital and physical experiences for brands, institutions and entertainment venuesNew on Evolcpressat.co.uk
Press release distribution and PR tools for businesses, brands and agencies seeking media coverage in the UK and internationallyNew on Evolcpressgazette.co.uk
Trade publication covering news, media businesses, technology and law for media professionals and industry leadersNew on Evolcpreventforfeandtraining.org.uk
Editorial rankings and reviews of online casinos and betting sites that accept UK players outside GAMSTOPNew on Evolcprimeinside.co.uk
Online publication of blog articles on fashion, tech, lifestyle, health and entertainment for general readersNew on Evolcprinceofteck.co.uk
Independent review portal with editorial guides to the Spinfin Casino platform for readers in the United KingdomNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
